Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-03
DOI
10.1186/s12967-020-02389-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
- (2020) Youhai Jiang et al. Frontiers in Immunology
- Immunotherapy in ovarian cancer: fake news or the real deal?
- (2019) Christian Marth et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication
- (2019) Rosalba De Nola et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
- (2019) Lin Wang Journal of Ovarian Research
- Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer
- (2019) Karolina Okła et al. Frontiers in Immunology
- A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward
- (2019) Ashley E. Stenzel et al. Frontiers in Immunology
- Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
- (2019) Paul Buderath et al. Frontiers in Oncology
- Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer
- (2018) Yoshikane Yamauchi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review
- (2018) Ying Zhu et al. BMC CANCER
- Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?
- (2018) Karolina Okla et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis
- (2018) Marcin Bobiński et al. Ginekologia Polska
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women
- (2018) Anne M. Mills et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
- (2018) Maureen L. Drakes et al. Journal of Ovarian Research
- The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
- (2018) S. J. A. M. Santegoets et al. OncoImmunology
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
- (2018) Galaxia Rodriguez et al. Cancers
- Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
- (2018) Maureen L. Drakes et al. Cancers
- Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200
- (2018) MICHAEL I. KOUKOURAKIS et al. ANTICANCER RESEARCH
- The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
- (2018) Boyang Chang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
- (2017) Jun Zhu et al. Journal of Gynecologic Oncology
- Ovarian Cancer: A Heterogeneous Disease
- (2017) Myriam Kossaï et al. PATHOBIOLOGY
- Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy
- (2017) Mengjiao Li et al. Journal of Ovarian Research
- Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients
- (2017) Liangliang Wu et al. Oncotarget
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
- (2017) Stephan Kruger et al. OncoImmunology
- The Dualistic Model of Ovarian Carcinogenesis
- (2016) Robert J. Kurman et al. AMERICAN JOURNAL OF PATHOLOGY
- Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
- (2016) S J L Mesnage et al. ANNALS OF ONCOLOGY
- Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
- (2016) Jayanta Chatterjee et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges
- (2016) Karolina Okła et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
- (2016) Naoki Takahashi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer
- (2016) Katarzyna Pogoda et al. Oncology Letters
- PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
- (2016) Tomoaki Iwata et al. Scientific Reports
- Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC
- (2015) Haitao Huang et al. TUMOR BIOLOGY
- Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
- (2015) Liang Wang et al. Oncotarget
- Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
- (2015) Silvia Darb-Esfahani et al. Oncotarget
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2
- (2013) Tracy X. Cui et al. IMMUNITY
- Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies
- (2012) Austin Duffy et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunosuppressive activity of CD14+ HLA-DR− cells in squamous cell carcinoma of the head and neck
- (2012) Kazuaki Chikamatsu et al. CANCER SCIENCE
- Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients
- (2012) Balázs Győrffy et al. ENDOCRINE-RELATED CANCER
- Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
- (2012) Athanasios Kotsakis et al. JOURNAL OF IMMUNOLOGICAL METHODS
- PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment
- (2011) N. Obermajer et al. CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Soluble B7-H1: Differences in production between dendritic cells and T cells
- (2011) Xavier Frigola et al. IMMUNOLOGY LETTERS
- Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
- (2008) Guangbo Zhang et al. IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More